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ABSTRACT Type I interferon (IFN)-stimulated genes (ISGs) have critical roles in in-
hibiting virus replication and dissemination. Despite advances in understanding the
molecular basis of ISG restriction, the antiviral mechanisms of many remain unclear.
The 20-kDa ISG ISG20 is a nuclear 3=–5= exonuclease with preference for single-
stranded RNA (ssRNA) and has been implicated in the IFN-mediated restriction of
several RNA viruses. Although the exonuclease activity of ISG20 has been shown to
degrade viral RNA in vitro, evidence has yet to be presented that virus inhibition in
cells requires this activity. Here, we utilized a combination of an inducible, ectopic
expression system and newly generated Isg20/ mice to investigate mechanisms
and consequences of ISG20-mediated restriction. Ectopically expressed ISG20 local-
ized primarily to Cajal bodies in the nucleus and restricted replication of chikungu-
nya and Venezuelan equine encephalitis viruses. Although restriction by ISG20 was
associated with inhibition of translation of infecting genomic RNA, degradation of vi-
ral RNAs was not observed. Instead, translation inhibition of viral RNA was associ-
ated with ISG20-induced upregulation of over 100 other genes, many of which en-
code known antiviral effectors. ISG20 modulated the production of IFIT1, an ISG that
suppresses translation of alphavirus RNAs. Consistent with this observation, the
pathogenicity of IFIT1-sensitive alphaviruses was increased in Isg20/ mice com-
pared to that of wild-type viruses but not in cells ectopically expressing ISG20. Our
ﬁndings establish an indirect role for ISG20 in the early restriction of RNA virus repli-
cation by regulating expression of other ISGs that inhibit translation and possibly
other activities in the replication cycle.
IMPORTANCE The host immune responses to infection lead to the production of
type I interferon (IFN), and the upregulation of interferon-stimulated genes (ISGs) re-
duces virus replication and virus dissemination within a host. Ectopic expression of
the interferon-induced 20-kDa exonuclease ISG20 suppressed replication of chikun-
gunya virus and Venezuelan equine encephalitis virus, two mosquito-vectored RNA
alphaviruses. Since the replication of alphavirus genomes occurs exclusively in the
cytoplasm, the mechanism of nucleus-localized ISG20 inhibition of replication is un-
clear. In this study, we determined that ISG20 acts as a master regulator of over 100
genes, many of which are ISGs. Speciﬁcally, ISG20 upregulated IFIT1 genes and in-
hibited translation of the alphavirus genome. Furthermore, IFIT1-sensitive alphavirus
replication was increased in Isg20/ mice compared to the replication of wild-type
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viruses but not in cells ectopically expressing ISG20. We propose that ISG20 acts as
an indirect regulator of RNA virus replication in the cytoplasm through the upregu-
lation of many other ISGs.
KEYWORDS alphavirus, host-pathogen interactions, innate immunity, interferon-
stimulated gene, virus-host interactions
Innate immune responses provide a ﬁrst line of defense against many pathogens andact to stimulate adaptive immune responses, which in turn help to clear infections
and generate lasting immunological memory. Stimuli from invading viruses trigger
pathogen recognition receptors that induce antiviral gene regulatory programs in
cell-intrinsic (e.g., antiviral effector proteins) and cell-extrinsic (e.g., cytokines) manners.
The most widely studied antiviral innate immune cytokine produced by this process,
type I interferon (IFN), signals through its heterodimeric receptor (IFNAR1/IFNAR2) on
infected and uninfected cells, activating the IFN-stimulated gene factor 3 complex
(ISGF3) to transcribe a targeted and yet large set of interferon-stimulated genes (ISG).
These ISGs control a variety of antimicrobial functions by indirectly or directly limiting
replication of the invading pathogen (1).
Alphaviruses are small, single-stranded RNA viruses (ssRNA) that are typically spread
via the bite of an arthropod vector. These include the arthritogenic viruses such as
chikungunya virus (CHIKV), Sindbis virus (SINV), and Ross River virus (RRV) and the
encephalitogenic viruses such as Eastern equine encephalitis virus (EEEV), Western
equine encephalitis virus (WEEV), and Venezuelan equine encephalitis virus (VEEV). This
genus of viruses includes emerging pathogens as well as one of the most pathogenic
RNA viruses (EEEV) for humans. Several studies have revealed a role for individual
IFN-upregulated effector proteins in controlling alphavirus infection (2–9). One ISG
with potent antiviral activity in vitro against alphaviruses is the 20-kDa exonuclease
interferon-stimulated gene 20 (ISG20) (3). ISG20 is a member of the RNA-speciﬁc DEDD
family of 3=-5= exonucleases that is localized predominantly in Cajal bodies, which are
dense subnuclear structures of protein and RNA (10–12). ISG20 has been shown to
restrict infection of multiple RNA and DNA viruses (3, 13–20). Due to the capacity of
ISG20 to degrade RNA nonspeciﬁcally in vitro and a more limited effect on DNA viruses,
it has been suggested that ISG20 functions as an antiviral by directly degrading viral
genomic RNA. However, this presumed activity has not been demonstrated in cells
where ISG20 and many viral RNAs localize to different subcellular compartments. For
example, the alphavirus genome replicates entirely within the cytoplasm of infected
cells and would not typically encounter a nucleus-localized protein.
We evaluated the antiviral activity of ISG20 and its effect on alphavirus replication.
Ectopic expression of ISG20 in ﬁbroblasts potently restricted the replication of multiple
alphaviruses through a block in viral translation but, unexpectedly, did not accelerate
the degradation of viral RNA. Nonetheless, the replication-blocking activity was depen-
dent on the presence of an intact ISG20 exonuclease domain. In the absence of viral
infection or IFN gene induction, ectopic expression of ISG20, but not a nuclease domain
mutant, induced expression of a suite of genes, many of which have described or
predicted antiviral activity. IFIT1 was consistently among the genes that were most
highly upregulated by ISG20 overexpression. IFIT1 has been shown to play a prominent
role in host cell recognition of non-self-RNAs and suppression of viral mRNA translation
(6). Although Isg20/mice were not more susceptible to infection with wild-type (WT)
pathogenic strains of CHIKV or VEEV, an IFIT1-sensitive mutant of VEEV was more
virulent in Isg20/ mice and replicated to higher levels in some, but not all, Isg20/
primary cells than in the WT counterparts. Taken together, our data suggest a role for
ISG20 as a regulator of steady-state and IFN-induced antiviral activity in selected cell
types.
(Portions of this work were uploaded to the D-Scholarship Institutional Repository at
the University of Pittsburgh as part of dissertation work [C. M. Weiss].)
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Murine ISG20 expression restricts alphavirus replication. We ﬁrst evaluated the
antiviral activity of murine ISG20 against CHIKV and VEEV, utilizing a stable, inducible
expression system in the absence of type I IFN treatment. Two separately derived clonal
cell lines were derived using tetracycline-inducible (tet-off) murine embryonic ﬁbro-
blasts (MEFs) expressing C-terminally FLAG-tagged murine ISG20; a mutant, ISG20D94G,
that is homologous to a human ISG20 mutant with disrupted exonuclease activity (Exo
II) (11); and enhanced green ﬂuorescent protein (eGFP) and ﬁreﬂy luciferase (fLuc) as
controls (3). We conﬁrmed the expression of each protein by Western blotting for the
FLAG epitope tag (Fig. 1A). Cellular localization of ectopically expressed ISG20 was
consistent with the published literature, forming dense nuclear puncta in confocal
micrographs (see Fig. S1A in the supplemental material), and this localization did not
change with virus infection (data not shown). To assess antiviral restriction by ISG20,
tet-off cells were induced for 72 h and infected with WT CHIKV or VEEV, as well as with
VEEV-G3A, which encodes an attenuating mutation in the 5=nontranslated region that
was acquired during cell adaptation of the TC83 vaccine strain of VEEV. This mutation
diminishes virulence in mice due to enhanced sensitivity to the antiviral effector activity
of IFIT1 (6). Ectopic expression of ISG20 in MEFs reduced infection of WT CHIKV and
VEEV by approximately 100-fold at 12 and 24 h postinfection (h.p.i.) (Fig. 1B and C).
However, replication in MEFs expressing the ISG20 ExoII mutant was similar to that seen
with cells expressing the GFP control, conﬁrming that the exonuclease of ISG20 was
essential for antialphavirus activity. VEEV-G3A was more sensitive to the antiviral effects
of ISG20, as infection was restricted completely at 6 and 12 h.p.i. by ISG20 expression
and was 1,000-fold lower at 24 h.p.i. than that seen with MEFs expressing the GFP or
ExoII mutant (Fig. 1D).
CHIKV or VEEV expressing GFP as a nonstructural protein 3 (nsP3) fusion (21) was
used to determine whether ISG20-dependent restriction was a result of fewer cells
initiating infection or represented a uniform reduction in replication efﬁciency. At 24 h
after infection, ﬂuorescence microscopy performed to assess GFP expression revealed
a lower percentage of GFP-positive cells (Fig. S1B) and reduced ﬂuorescence intensity
(Fig. S1C), suggesting that ISG20 inhibited overall replication efﬁciency. Again, the
ISG20 ExoII mutant did not inhibit CHIKV or VEEV infection as the percentage of
infected cells was similar to the percentage of control cells expressing fLuc.
ISG20 expression blocks viral genome translation. To explore the mechanism
behind ISG20 suppression of virus replication, we infected tet-off MEFs expressing
ISG20, ExoII, or GFP with a CHIKV strain expressing nanoluciferase (nLuc) in nsP3 as a
reporter for the translation of the incoming virus genome. The signiﬁcant reduction
in CHIKV nsP3 reporter signal in the presence of ISG20 at early time points (e.g., 6 h
postinfection; Fig. 2A) suggested a possible inhibition of the translation of the incoming
nonstructural polyprotein. To evaluate this more directly, we tested whether ISG20
could inhibit the translation of incoming 5= capped RNA using reporters encoding only
the 5= and 3= nontranslated regions of a generic RNA (host) or the 5= and 3= nontrans-
lated regions of CHIKV fused inframe with a ﬁreﬂy luciferase mRNA sequence (Fig. 2B)
(22). Transfection of these RNAs into MEFs expressing GFP, ISG20, or ExoII revealed a
signiﬁcant decrease in peak translation of the host RNA (Fig. 2C) and CHIKV reporter
RNA (Fig. 2D) when ISG20, but not Exoll, was expressed. Internal ribosomal entry site
(IRES) sequences can be utilized by some RNAs to initiate translation without the use
of components of the cap-dependent translation machinery (23). The IRES from en-
cephalomyocarditis virus (EMCV) requires some cap-dependent translation initiation
factors (IFs) to initiate translation, whereas the IRES used by cricket paralysis virus (CrPV)
does not utilize this pathway for translation initiation (23). Notably, transfected EMCV-
IRES and CrPV-IRES reporters were unaffected by ISG20 expression (Fig. 2E and F). These
data suggest that ISG20 expression blocks only cap-dependent translation initiation
rather than inducing global inhibition of protein synthesis in MEFs. These data are
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similar to results obtained by evaluating the effects of interferon alpha-beta (IFN-/)
treatment on translation of virus reporter RNAs in cells (24).
ISG20 expression does not accelerate decay of the CHIKV RNA 3= terminus.
ISG20 was previously characterized as a 3=–5= exoribonuclease capable of degrading
FIG 1 Inducible expression of murine ISG20 suppresses alphavirus replication. (A) Two clones of tet-off
MEFs expressing FLAG-tagged eGFP, murine ISG20, or the exonuclease domain mutant murine ISG20D94G
(ExoII) were induced for 72 h and then immunoblotted for the FLAG-tagged protein. DOX, doxycycline.
(B to D) Induced tet-off MEFs were infected with (B) WT CHIKV, (C) WT VEEV, or (D) VEEV-G3A (MOI of 0.1).
Replicated virus levels were measured in cell supernatants by BHK-21 plaque assay. *, P  0.5; ***, P 
0.001 (2-way ANOVA with Holm-Sidak post hoc analysis against eGFP control) (n  6, 2 independent
experiments).
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FIG 2 ISG20 suppresses translation of non-IRES-containing capped mRNA. (A) tet-off MEFs overexpress-
ing the indicated protein were infected with CHIKV-nsP3-nLuc nonstructural reporter virus at an MOI of
0.1, and lysates were collected at the indicated time points. Reporter signal data are given as ratios of
relative luminescence units normalized to cellular protein levels in micrograms (RLU/g). ***, P  0.001
(2-way ANOVA with Holm-Sidak post hoc analysis against GFP control) (n  6, 2 independent experi-
ments). (B) Schematic representation of type 0 capped and polyadenylated nonreplicating translation
reporters. The luciferase gene is ﬂanked by 5= and 3= nontranslated regions for the indicated mRNA. The
CHIKV reporter also encodes the translational initiation sequences of the nsP1 protein (diagonal lines).
(C to F) Induced tet-off MEFs overexpressing the indicated protein were electroporated with 7.5 g of
indicated RNA and then sampled for 4 h. Relative luminescence at 3 h is given as a percentage of the
initial signal at 30 min. (C) Host reporter. (D) CHIKV reporter. (E) EMCV reporter. (F) CrPV reporter. **, P 
0.01 (2-way ANOVA with Holm-Sidak post hoc analysis against eGFP control) (n  6, 2 independent
experiments).
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nonspeciﬁc RNA targets in a processive manner in vitro (11). Testing the effects of ISG20
expression on degradation of viral RNA requires introduction of RNA into the cell
cytoplasm and inhibition of RNA replication. Cycloheximide, a potent global inhibitor of
translation, completely blocks translation of the CHIKV RNA (Fig. 3A), which inhibits
virus replication. Induced tet-off MEFs expressing ISG20, ExoII, or control GFP were
infected with CHIKV (multiplicity of infection [MOI] of 5) and treated with cyclohexi-
mide. Primers for quantitative real-time PCR (qRT-PCR) were designed to target the 3=
terminus of CHIKV to detect the earliest signs of degradation within the 3= nontrans-
lated region. qRT-PCR analysis revealed no signiﬁcant differences in the number of
FIG 3 ISG20 expression does not accelerate degradation of CHIKV RNA. (A) MEFs were infected with
CHIKV expressing nLuc in frame with the nsP3 nonstructural protein at an MOI of 5 and then treated with
0 or 10 M cycloheximide (Cyc) to block translation and, ultimately, replication of CHIKV RNA. (B) MEFs
were infected with CHIKV-LR (MOI  5) and then treated with 10 M cycloheximide. RNA was collected
at the indicated time p.i. and analyzed by qRT-PCR for the CHIKV 3= terminus. (B) Data represent results
of 2-way ANOVA with Holm-Sidak post hoc analysis against eGFP control. (n  6, 2 independent
experiments; data were not statistically signiﬁcant). (C) RNA isolated from ISG20 MEFs is functional. The
CHIKV-translation reporter was isolated from tet-off MEFs overexpressing GFP, ISG20, or ExoII mutant,
retransfected into MEFs expressing either GFP or ISG20 for 3 h, and assayed for ﬁreﬂy luciferase reporter
activity, and luciferase activity data from second transfections are given as ratios of ﬁreﬂy luciferase
signals from h 3 versus h 0 samples taken from ﬁrst transfection. Data represent results of ANOVA with
Dunnett’s post hoc analysis against GFP control (n  6, 2 independent experiments; data were not
statistically signiﬁcant).
Weiss et al.












CHIKV genomes in the GFP, ISG20, or ExoII tet-off MEFs over time (Fig. 3B), demon-
strating that ISG20 expression does not accelerate the decay of CHIKV RNA. This result
is similar to our previous results demonstrating that Sindbis virus RNA is not degraded
in IFN-treated cells that have upregulated ISGs, including ISG20 (24).
To conﬁrm that ISG20 expression does not degrade CHIKV RNA, we electroporated
the CHIKV-translation reporter RNA into cells expressing GFP, ISG20, or ExoII. After 0 h
and 3 h, total cellular RNA was harvested and reelectroporated into either GFP-
expressing cells or ISG20-expressing cells and analyzed for luciferase activity. If ISG20
were degrading CHIKV RNA, we would expect to observe less translation from the
CHIKV RNA isolated from ISG20-expressing cells at 3 h than at 0 h. We observed similar
levels of translation activity of the 3 h and 0 h samples (ratio, 1) after reelectropo-
ration into GFP control cells lacking ISG20 expression (Fig. 3C), demonstrating that prior
exposure to ISG20 did not functionally inhibit the CHIKV translation reporter. Overall,
these data demonstrate that ISG20 expression does degrade CHIKV RNA in ISG20-
overexpressing MEFs.
ISG20 expression regulates a focused gene signature. Type I IFN signaling and
gene induction inhibit alphavirus translation through the actions of multiple gene
products (2, 24). Since both alphavirus replication and translation reporter activity were
inhibited strongly by ISG20 in the absence of effects on RNA stability, which resembled
the effect of IFN-/ treatment, we transcriptionally proﬁled cells to determine if
antiviral mechanisms or ISGs were altered in the ISG20-expressing cells. We performed
RNA sequencing (RNA-seq) on two independently generated clones of the tet-off MEFs
expressing GFP, ISG20, or ExoII. Using two clones of each cell type ensured that stable
expression of the proteins did not generate an outlier cell population. In the absence
of infection, MEFs expressing ISG20 revealed an IFN-like pattern of gene expression
even though exogenous IFN was not added. The most highly upregulated genes, which
exhibited 5-fold or greater induction compared to both control and ExoII mutant cells,
were annotated as antiviral or inducible by type I or II IFN (Fig. 4A). However, IFN-/,
IFN-, or IFN- genes were not upregulated signiﬁcantly by ISG20 expression, as
determined by RNA-seq or qRT-PCR (data not shown). Among the top gene targets
identiﬁed were those encoding several IFN-inducible proteins with tetratricopeptide
repeats (Iﬁt family), including Iﬁt1 and Iﬁt3, as well as other Iﬁt-like genes (Fig. 4B). Not
all of the Iﬁt family genes were upregulated by ISG20 expression; Iﬁt2 was an exception.
Members of several other gene families were induced, including the ubiquitin-like
Isg15, the ISG15 E3 ligase, Herc6, and the de-ISGylating Usp18 (Fig. 4B). Upregulated
genes also included multiple IFN response pathway transcription factor genes (e.g., Irf7,
Irf9, Stat1, and Stat2) and the viral RNA-sensing helicase gene Ddx58 (RIG-I). Network
analysis of ISG20 overexpression highlighted a pattern similar to that seen with viral
infection or IFN responses but without the induction of primary signaling components
of type I, II, or III IFN or their receptors. In addition to the IFN-like responses, the levels
of eukaryotic initiation factor 2 (eIF2) signaling, eIF4 signaling, and mTOR signaling, all
affecting translation efﬁciency, were increased in response to ISG20 ectopic expression
in MEFs (Fig. 4A). Upregulation of the most signiﬁcantly induced set of genes from
RNA-seq was conﬁrmed by qRT-PCR in ISG20 (Fig. 5A). Iﬁt1 was consistently upregu-
lated 10-fold over baseline levels in cells ectopically expressing ISG20 compared to
the cells expressing GFP and ExoII. The ISG20-mediated upregulation in Iﬁt1 mRNA
levels also led to increased IFIT1 protein expression in the cells that required a
functional ISG20 protein (ExoII) (Fig. 5B and C).
Gene induction by ISG20 requires IRF3 expression. Many of the genes upregu-
lated in the context of ISG20 expression are also upregulated by interferon regulatory
factor 3 (IRF3) activation (25). The pathway analysis of the ISG20-regulated genes
implicated IRF3 as a prime candidate for regulating the ISG20 response (data not
shown). To assess the role of IRF3 in mediating ISG20-dependent induction of ISGs, we
transfected luciferase plasmids containing the complete IFN- promoter or its constit-
uent two IRF3-binding elements or one NF-B-binding element into our MEFs. ISG20
Role of ISG20 during Alphavirus Infection












FIG 4 ISG20 expression induces antiviral gene transcription. RNA-seq was performed on two sepearte clones of
MEFs expressing eGFP, ISG20, or ExoII. (A) Differential gene expression was analyzed, and upregulated canonical
pathways are shown. Numbers on top of each column indicate the total number of genes investigated in each
pathway. (B) A heat map of the most signiﬁcant ISG20-induced genes is shown. Temperature ranges are shown as
fragments per kilobase of transcript per million mapped reads (FPKM) from green (low) to red (high). P  0.001
(Cuffdiff 2 gene expression model; false-discovery rate [FDR]  5%).
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expression led to a signiﬁcant increase in luciferase expression in cells transfected with
the entire IFN- promoter as well as in cells transfected with the partial promoters
containing only the two IRF3 components (Fig. 6A). Luciferase expression was also
increased in ISG20-expressing cells transfected with the NF-B element alone, suggest-
ing that ISG20 expression may also drive NF-B promoter activity (Fig. 6A). Poly(I·C)
treatment led to the stimulation of the complete IFN- promoter and its constituent
elements in both GFP control cells and the ISG20-expressing cells, demonstrating that
IFN treatment can also lead to NF-B and IRF3 promoter activity in the absence of ISG20
FIG 5 ISG20 induces a subset of antiviral genes. tet-off MEFs expressing eGFP, ISG20, or ExoII mutant were
induced for 72 h, and total cellular RNA and protein were collected. (A) A selection of genes shown to be
induced by ISG20 overexpression through RNA sequencing were conﬁrmed by qRT-PCR (n  6, 2
independent experiments). NC, no change. (B and C) IFIT1 protein induction was conﬁrmed by Western
blotting (B) and quantiﬁed (C). (A and C) *, P  0.05; **, P  0.01 (Mann-Whitney test). (For panels B and
C, n  2, 2 independent experiments).
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overexpression (Fig. 6A). Expression of the Exoll ISG20 mutant did not drive promoter
activity of the complete IFN- promoter or its constituent elements, and the results
actually trended toward reduced promoter activation after poly(I·C) treatment (Fig. 6A).
Furthermore, small interfering RNA (siRNA) knockdown of IRF3 in tet-off MEFs express-
ing ISG20 revealed a signiﬁcant reduction in ISG20-modulated gene upregulation
versus the results seen with a nontargeting control siRNA (Fig. 6B). However, in MEFs
expressing ISG20, no detectable secretion of IFN-/ (Fig. 6C) or upregulation of IFN
genes (data not shown) was observed, demonstrating the role of ISG20 gene regulation
in the absence of IFN production. Although the presence of IRF3 appears critical for
ISG20 gene upregulation, analysis of IRF3 activation in the MEFs by assessment of
phosphorylation at serine 396 or of nuclear migration of the protein by cell fraction-
ation or antibody staining/confocal microscopy did not demonstrate activation/nuclear
localization (data not shown). Together, these ﬁndings suggest that IRF3 contributes to
the transcription proﬁle observed with ISG20 expression; however, activation of the
canonical pathway of IRF3 phosphorylation and nuclear migration is not observed.
ISG20 inhibits replication of IFIT1-sensitive but not WT alphaviruses in mice.
Given the restriction observed with ectopic expression of ISG20 in MEFs, we sought to
FIG 6 ISG20 expression activates transcriptional pathways involving IRF3. (A) MEFs expressing eGFP, ISG20, and ExoII were induced and
transfected with the luciferase driven by the IFN- promoter (pLUX) or the IRF3 responsive elements (PRDI/III) or the NF-B element of
the IFN- promoter (PRDII) along with a SV40 promoter-driven Renilla plasmid. Fireﬂy luciferase RLUs were normalized to Renilla RLUs, and
induction data are given as percentages of untreated GFP cell results. (B) MEFs expressing GFP, ISG20, and ExoII mutant were induced and
treated at 24 h with siIrf3 or siRNA scramble for an additional 48 h. Selected genes were assessed by qRT-PCR, and induction levels are
given as fold changes from sham-treated GFP control results. (C) IFN levels were measured in the tet-off MEF cell culture supernatant
before and after poly(I·C) lipid transfection. *, P  0.05; **, P  0.01; ***, P  0.001. (A and C) ANOVA with Dunnett’s post hoc analysis (n 
6, 2 independent experiments). (B) Mann-Whitney test (n  6, 2 independent experiments).
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verify our ﬁndings in a mouse model of CHIKV infection and musculoskeletal disease
(26–28). Wild-type C57BL/6 (B6) and Isg20/ male mice (3 weeks of age) were
inoculated subcutaneously with 103 PFU of CHIKV in the left rear footpad, and joint and
tissue inﬂammation was tracked by direct measurement of swelling. Unexpectedly, we
observed no differences in the levels of foot swelling between Isg20/ and B6 mice
after CHIKV infection (Fig. S2A). Furthermore, serum, ipsilateral foot, and draining
popliteal lymph node (PLN) samples from WT and Isg20/ mice showed no signiﬁcant
differences in viral RNA levels (Fig. S2B). In addition, serum IFN-/ was not detectable
in infected B6 and Isg20/ mice at 24 h.p.i. (data not shown).
Neonatal pups lacking a fully developed immune system also can be used to assess
differences in CHIKV pathogenesis between mouse strains through differences in
survival times. Due to underdeveloped immune responses, loss of even a single ISG can
result in susceptibility phenotypes (29, 30). Isg20/ and B6 pups were inoculated with
103 PFU of CHIKV subcutaneously in the axial region and housed with a surrogate WT
mother. Pups succumbing to disease earlier than 6 days p.i. manifested symptoms
indicative of a systemic inﬂammatory response syndrome-like disease as observed with
Sindbis virus (31). After 6 days, neurological signs developed consisting of ataxia
progressing to hind limb paralysis. Notably, no differences in mean survival times or
neurological disease manifestations were observed between Isg20/ and B6 neonatal
mice infected with WT CHIKV (Fig. S3). Thus, although CHIKV infection is modulated by
ectopic expression of ISG20 in vitro in MEFs, restriction in mice does not appear to be
inﬂuenced by the absence of ISG20.
IFIT1, which functions as an antiviral molecule that restricts virus translation (3, 6),
was highly upregulated by ISG20 expression. The VEEV-G3A mutation disrupts the
terminal stem-loop structure in 5=nontranslated regions, which allows IFIT1 recognition
of the alphavirus type 0 cap structure, which is normally evaded by pathogenic strains
(6). Age-matched, adult male mice were inoculated subcutaneously with 103 PFU of
VEEV WT or VEEV-G3A, and morbidity and mortality were monitored. VEEV WT-infected
Isg20/ mice demonstrated a slightly earlier onset of symptoms, with clinical mani-
festations in B6 mice following about 24 h later (Fig. S4A and B). However, weight loss
(Fig. S4C) and the median survival times for mice infected with VEEV WT were
essentially equivalent at 5.5 and 5.8 days for B6 and Isg20/ mice (Fig. S4D). Isg20/
mice infected with VEEV-G3A displayed a worse disease score than B6 mice and
developed neurological signs sooner than WT mice (Fig. 7A and B). Additionally,
Isg20/ mice experienced more-rapid weight loss than WT mice after VEEV-G3A
infection (Fig. 7C). Finally, Isg20/ mice uniformly succumbed to VEEV-G3A infection,
whereas 50% of WT animals recovered by 12 days p.i. The median survival times after
VEEV-G3A infection were 11 and 7 days in WT and Isg20/ mice, respectively (Fig. 7D).
Innate immune responses within the ﬁrst 24 h of infection often determine disease
outcome, as the induction of the type I IFN response slows dissemination and primes
the adaptive immune response. We measured VEEV-G3A burden and type I IFN levels
in different tissues to determine the extent of virus replication and spread early (at 12
and 24 h.p.i.) and again at 5 days, when neurological symptoms typically appeared. At
12 h.p.i., we detected a 5-fold increase in serum IFN-/ levels in B6 compared to the
results seen with Isg20/ mice (P  0.01). However, the serum IFN levels in Isg20/
mice increased to levels similar to those seen in B6 mice by 24 h.p.i. (Fig. 7E). VEEV-G3A
infection in the draining popliteal lymph node (PLN) was elevated in Isg20/ mice
compared to B6 mice at 12 h.p.i. (Fig. 7F). By 24 h.p.i., all WT mice had evidence of
infection in their PLN, a time point at which time viremia was elevated 2-fold in
Isg20/ mice (P  0.05, Fig. 7F and G). By 5 days p.i., VEEV-G3A was undetectable in
serum, PLN, or the spleen in both B6 and Isg20/ mice (Fig. 7F to H). Virus was
measured at greater than 105 PFU/mg in the brain at 5 days p.i. in B6 and Isg20/
mice, with the latter strain trending toward higher levels (Fig. 7I). No other signiﬁcant
differences in virus replication were detected in the spleen or the brain at any time
point examined. IFN- mRNA levels also were consistently lower in the PLN of Isg20/
mice than in that of B6 mice infected with VEEV-G3A, with fewer IFN- transcripts also
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FIG 7 Isg20/ mouse data support the idea of increased virulence of the IFIT1-sensitive VEEV-G3A mutant. (A to D) B6 and Isg20/ mice
received bilateral subcutaneous inoculations of 103 PFU of VEEV-G3A in rear footpads and were monitored for signs of disease based on (A
(Continued on next page)
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observed at 5 days p.i. in the spleen (Fig. 7K). IFN- mRNA levels in the brain remained
consistent between B6 and Isg20/ mice across all time points tested (Fig. 7J to L).
Primary cells from Isg20/ mice are more susceptible to CHIKV and VEEV
infections. The observed differences in viral replication suggest that ISG20 may
participate in orchestrating innate immune responses in particular cell types, which
affects the outcome of infection with IFIT1-sensitive viruses, which are less able to
evade host antiviral responses. To begin to determine the cell-speciﬁc effects of an
ISG20 deﬁciency, primary MEFs and osteoblasts were generated from sex- and age-
matched wild-type and Isg20/mice; these cells represent possible early target cell
types for CHIKV and VEEV in vivo (22, 32). In the absence of type I IFN priming, CHIKV
replicated to 10-fold-higher levels by 24 h in Isg20/ MEFs than in WT MEFs (P 
0.01) (Fig. 8A). When MEFs were primed with 10 and 100 IU of IFN-4/ at a 1:1 ratio
for 4 h, we observed similar differences in virus replication, with 10-fold-greater
infection in Isg20/MEFs than in B6 MEFs. In osteoblasts, only a minimal increase in
CHIKV infection was detected in Isg20/ compared to B6 mice in the absence of IFN
priming (Fig. 8B). After IFN priming, CHIKV replicated to similar levels in Isg20/and B6
osteoblasts, demonstrating cell-speciﬁc differences in ISG20-mediated antiviral effects
(Fig. 8B). More-dramatic differences were observed with VEEV-G3A, as Isg20/ MEFs
exhibited a 100-fold to 10,000-fold increase in VEEV-G3A infection compared to WT
MEFs (P  0.01) (Fig. 8C). These differences were maintained in the presence of IFN
treatment, as B6 MEFs released no detectable virus at 24 h.p.i. (Fig. 8C). VEEV-G3A also
replicated to higher levels after IFN treatment in Isg20/ primary osteoblasts than in
B6 cells, albeit with 5-fold to 100-fold differences at 24 h.p.i. (P  0.01) (Fig. 8D). The
differences in primary cells indicate that ISG20-mediated gene regulation likely con-
tributed to the antialphavirus proﬁle and activity of ISGs. To determine whether IFN
pretreatment of the primary B6 and Isg20/ MEFs led to the upregulation of antiviral
ISGs, we measured the induction of the same genes that were upregulated in ISG20-
overexpressing MEFs (Fig. 5). Iﬁt1 induction was reduced by 2-fold in Isg20/ MEFs
compared to B6 MEFs in response to low-dose (10 IU/ml) IFN treatment (P  0.05)
(Fig. 8E) but was abolished in response to higher-dose (100 IU/ml) IFN treatment. Isg15
and Oas1a induction was also reduced in Isg20/ MEFs compared to B6 MEFs, and
both are known antiviral ISGs that restrict virus replication (3, 33, 34).
DISCUSSION
Type I IFN-stimulated genes have multiple roles in suppressing infection of many
RNA and DNA viruses. Over 300 gene products can be induced by type I IFN, creating
a broadly restrictive environment for both microbial and viral pathogens. The inhibitory
activity of numerous ISGs has now been elucidated through extensive ectopic expres-
sion and short hairpin RNA (shRNA) proﬁling studies (3, 4, 35, 36), but the antiviral
activity of many remains elusive. ISG20 was ﬁrst biochemically characterized as an
IRF1-induced gene with high homology to DEDD domain nucleases in the same family
as the Saccharomyces cerevisiae rex4p gene (11, 37). ISG20 was demonstrated in vitro to
have 3=–5= exonuclease activity enabling nonspeciﬁc degradation of single-stranded
nucleic acid substrates with a preference for RNA (11). Because mutations in the
endonuclease catalytic domain abrogated antiviral activity, it has been hypothesized
that ISG20 directly degrades viral RNA to achieve its antiviral effect (11, 13).
The antiviral activity of ISG20 in cell culture has been demonstrated in ectopic
expression studies for a number of RNA viruses (3, 13–20), including the prototypical
alphavirus, SINV (3). However, those studies did not deﬁne the mechanism of ISG20
FIG 7 Legend (Continued)
and B) clinical scoring of behavior, (C) weight loss, and (D) average survival. (E) Mice were sacriﬁced and perfused at the indicated time point,
and tissues were assessed for serum IFN. (F to I) Virus replication was measured in (F) popliteal lymph node, (G) serum, (H) spleen, and (I)
brain at the indicated time points. (J to L) IFN- mRNA was measured in (J) popliteal lymph node, (K) spleen, and (L) brain after VEEV-G3A
infection. Data are represented as fold change in IFN- compared to mock treatment results. *, P  0.05; **, P  0.01. (D) log-rank test (n 
6 mice, 2 independent experiments). (E to I) Multiple Student’s t tests (n  8 mice, 2 independent experiments). (F) Mann-Whitney test (n 
8 mice, 2 independent experiments).
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FIG 8 A deﬁciency of ISG20 leads to increased CHIKV and VEEV-G3A replication in primary cells. Primary cells were isolated from age-
and sex-matched B6 and Isg20/ mice. Cells were treated with 0, 10, or 100 IU/ml IFN-4/ (1:1 ratio) for 4 h and then infected with
(A and B) CHIKV or (C and D) VEEV-G3A (MOI 1). Virus titers were determined at 24 h.p.i. by plaque assay. (E) ISG induction was
measured in uninfected, 6-h IFN-treated B6 or Isg20/MEFs by qPCR. *, P 0.05; **, P 0.01; ***, P 0.001 (multiple Student’s t tests).
(A to D) n  6, 2 independent experiments. (E and F) n  3, 2 independent experiments.
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restriction of replication in cells or animals. In the present study, we established a model
system for determining the molecular basis of the restriction by murine ISG20. Stable
ectopic expression of the dominant splice variant of murine ISG20 (isoform b), which
shows 82% identity with human ISG20, inhibited CHIKV and VEEV replication in vitro,
consistent with earlier ﬁndings determined with SINV. Introduction of a homologous
glycine mutation at the D94 catalytic aspartate in the ExoII nuclease domain abrogated
the antiviral activity of ISG20 in vitro, consistent with the published role of ISG20
catalytic activity in its antiviral function. However, in cells ectopically expressing the
protein, the primary antiviral activity of ISG20 against alphaviruses occurred indirectly,
through upregulation of subsets of IFN response genes.
Recent reports have suggested that ISG20 may mediate viral RNA degradation.
Studies performed with hepatitis B virus (HBV) suggested that ISG20 restricts viral
replication by directly degrading viral RNAs and genomic intermediates produced over
the course of infection (20, 38). In our cell culture model, the 3= terminus of the CHIKV
genome did not undergo ISG20-mediated degradation, and viral RNAs were translation
competent after exposure to the cytoplasm of ISG20-expressing cells, consistent with
results obtained with IFN pretreatment of cells, which induces ISG20, among other
cellular nucleases (24). Unlike HBV, the alphavirus RNA genome is replicated entirely in
the cytoplasm and should not be exposed to the nuclear puncta that contain ISG20 and
thus are not likely to be exposed to signiﬁcant levels of ISG20 protein. These results are
consistent with a previous study showing that ISG20 did not degrade or inhibit
hepatitis C viral RNA, which is also localized in the cytoplasm (18).
Another study suggested that ISG20 directly interacts with inﬂuenza A viral proteins
to block translation, binding speciﬁcally to the inﬂuenza virus nucleoprotein to facilitate
this activity (19). One caveat with these experiments pertained to the abnormal
distribution of ISG20 observed in a transient overexpression system, which favored a
cytoplasmic localization, even in the absence of inﬂuenza virus nucleoprotein. In our
experimental system, we observed the punctate, primarily nuclear localization of the
tagged ISG20, consistent with previous studies (12). We also observed ISG20-speciﬁc
restriction of virus RNA reporter translation. As translation restriction was not observed
for reporter RNA containing an internal ribosomal entry site from EMCV or CrPV, it is
likely that the block in translation is the result of the cap-dependent initiation mech-
anism and does not represent a general reduction in protein synthesis or mRNA
stability. Notwithstanding these data, it is possible that ISG20 employs multiple mech-
anisms of translation restriction depending upon the virus. In light of recent work with
HBV demonstrating ISG20 accumulation on particular secondary structures within viral
RNAs, ISG20 may restrict nuclear replication of RNA viruses through direct binding
and/or degradation (38). Indeed, HBV RNA binding by the catalytically inactive
ISG20D94G was preserved and contributed to an observed translation-suppressing
phenotype (38). However, ISG20D94G did not arrest translation of the alphavirus report-
ers, suggesting that direct RNA binding by ISG20 is not the primary mechanism of
alphavirus translation suppression.
The localization of ISG20 may offer insight with respect to its mechanism of antiviral
action. Despite its being a small, soluble protein capable of free diffusion through the
nuclear pore complex, ISG20 localizes to the nucleus and interacts with the protein- and
RNA-rich Cajal bodies (12). The primary purposes of these structures are the processing
and modiﬁcation of small nuclear RNAs that comprise the spliceosome (39, 40),
suggesting that ISG20 may inﬂuence cytosolic virus replication through these addi-
tional mechanisms. In fact, it has been proposed that ISG20 could target the expression
of host microRNA or long noncoding RNAs, which could regulate the expression of
many different genes (38, 41). Our transcriptional analysis of MEFs ectopically express-
ing ISG20 revealed more than 100 upregulated genes that required the ISG20 exonu-
clease, including two interferon regulatory factor (Irf) genes, the cytoplasmic viral
RNA-detecting helicase RIG-I gene (Ddx58), and genes encoding members of the
IFN-induced protein with tetratricopeptide repeats (IFIT) family. Iﬁt1 upregulation
stands out in particular, because it inhibits translation of type 0 capped RNA in a
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manner consistent with our ﬁndings with respect to ISG20 expression (6); however,
other ISGs could also contribute to the effects observed.
Among the alphaviruses, CHIKV is susceptible to murine type I IFN responses, and
this effect has been attributed to numerous individual effector proteins (9, 30, 42–45).
VEEV, by comparison, infects rodents as a reservoir host and has evolved mechanisms
to evade the murine IFN response (46, 47). The VEEV-G3A mutant, with a single
nucleotide mutation in the 5= UTR, is attenuated in WT B6 mice, due, at least in part, to
the action of Iﬁt1, an ISG that is also highly expressed in our cells overexpressing ISG20
(6). In our studies, VEEV-G3A was more virulent in the Isg20/ mice than in the WT B6
mice. In addition, lower levels of serum IFN-/ were detected by 12 h in the Isg20/
mice concomitant with an increase in virus replication in the lymph node. The atten-
uation of the VEEV-G3A mutant was previously shown to be highly dependent on
IFN-/ responses (48) and also on IFIT1 (6) speciﬁcally. Additionally, the tested
Isg20/ primary cells showed increased susceptibility to alphavirus infection, even in
the presence of IFN priming. The reduced induction of Iﬁt1, Isg15, and Oas1a mRNA
levels that we observed in the primary Isg20/ MEFs compared to B6 MEFs after IFN
treatment may be sufﬁcient for VEEV-G3A escape of IFIT1-mediated repression. How-
ever, in vivo, the increased susceptibility of Isg20/ mice to VEEV-G3A infection may
also be due to interferon induction differences, which may or may not be related to
differences in upregulation of the speciﬁc ISGs identiﬁed in our in vitro screens.
Combined with our understanding of IFN-mediated ISG20 upregulation and ISG20-
mediated upregulation of IFIT1 and other antiviral effectors in vitro, the mouse model
of VEEV-G3A suggests a feed-forward mechanism by which ISG20 ampliﬁes IFN and ISG
production in response to infection. The failure of the ISG20-expressing ﬁbroblasts to
produce IFN-/ may reﬂect cell type-dependent differences in the effect of ISG20.
We propose a model where expression of ISG20 blocks incoming alphavirus genome
translation and possibly other replication activities through the modulation of antiviral
ISGs. This modulation of the host antiviral environment is achieved through a direct
upregulation of ISGs possibly involving IRF3 and, in vivo, augmented by a positive loop
of IFN production. Future studies should elucidate the extent to which IFIT1 is respon-
sible for alphavirus translation inhibition and whether alternative mechanisms are at
play, as well as whether or not a noncanonical activity of IRF3 is involved in mediating
the ISG20 signal.
MATERIALS AND METHODS
tet-off MEF cells. tet-off murine embryonic ﬁbroblasts (MEFs) expressing ISG20, enhanced green
ﬂuorescent protein (GFP) control, or ﬁreﬂy luciferase (fLuc) control genes were previously described, and
tet-off MEFs expressing ISG20D94G (ExoII) cells were generated similarly (3). The ExoII gene was made by
aligning the human and mouse sequences and mutating the active site of the exonuclease to match the
human ExoII nuclease-deﬁcient mutant (13). tet-off MEFs were maintained in complete media consisting
of Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 200 mM L-glutamine, 10,000 units/ml penicillin, 10 mg/ml streptomycin, 100 g/ml G418
sulfate, and 100 g/ml hygromycin sulfate. Gene overexpression was suppressed with the addition of
2 g/ml doxycycline hyclate (Sigma) for cell expansion prior to experiments.
Ectopic expression of target genes. tet-off MEFs were trypsinized and washed in sterile phosphate-
buffered saline (PBS) three times, plated, and induced in doxycycline-free, complete tet-off MEF media
for 72 h prior to use. Gene expression was conﬁrmed by both qRT-PCR and Western blotting for these
conditions. All cells were grown to approximately 80% conﬂuence for optimal infection and transfection
conditions in subsequent experiments.
Western blotting. MEFs were induced for 72 h as described above and then lysed in radio
immunoprecipitation assay buffer with protease and phosphatase inhibitors (2). Cell wall debris was
cleared by centrifugation, and 20 ng of protein was electrophoresed on 5%/10% SDS polyacrylamide
discontinuous gels. Gels were transferred to a polyvinylidene diﬂuoride (PVDF) immunoblotting mem-
brane by semidry transfer and blocked with 5% nonfat milk–Tris-buffered saline–0.1% Tween 20 (TBS-T)
for 1 h. Anti-FLAG M2-peroxidase conjugate (1:2,000) was applied for 2 h at room temperature, or rabbit
anti-mIﬁt1 (1:1,000) was applied overnight at 4°C with agitation. Secondary detection of IFIT1 was
performed by thoroughly washing in TBS-T followed by goat anti-rabbit horseradish peroxidase (HRP)
conjugate (1:2,000) for 1 h at room temperature. Blots were thoroughly washed prior to detection with
Pierce ECL detection reagent (Thermo Scientiﬁc) and exposure to chemiluminescence ﬁlm (GE Health-
care).
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Viruses. The wild-type CHIKV la Réunion (CHIKV-LR) cDNA clone (49) was a gift from Stephen Higgs
(Kansas State University). The WT VEEV (ZPC738) and VEEV-G3A cDNA clones were published previously
(48, 50). eGFP or nanoluciferase (nLuc) was inserted into CHIKV or VEEV cDNA clones either in nsP3
nonstructural protein or in the structural proteins as a self-cleavable protein (Thosea asigna virus [TaV])
as previously described (21). Viruses were generated from infectious cDNA clones after in vitro transcrip-
tion with SP6 polymerase (mMessage mMachine; Ambion) and electroporation in BHK-21 cells. Super-
natants were collected at 24 h and centrifuged to remove cell debris prior to freezing in aliquots at
80°C. All viral titers were determined by BHK-21 plaque assay and are expressed in PFU per milliliter.
Virus growth assays. A 50-l volume of supernatant was collected from infected cells at various
times postinfection, and virus titers were determined by plaque assay on BHK-21 cells. nLuc reporter-
virus infected cells were washed 3 times in PBS, lysed in luciferase passive lysis buffer, and then frozen
to aid in complete disruption of cellular membranes. A 25-l volume of each sample lysate was
combined with 25 l of prepared NanoGLO chemiluminescent reagent and incubated for 6 min at room
temperature. Chemiluminescent signal was detected on a luminometer, quantiﬁed as relative light units,
and normalized to individual sample protein concentrations determined by bicinchoninic acid (BCA)
protein assay.
Immunoﬂuorescence microscopy. Cells grown on glass coverslips were ﬁxed in 4% paraformalde-
hyde for 15 min and permeabilized with 0.1% Triton X-100–PBS for 15 min. Fixed cells were rehydrated
in PBS–0.5% BSA (PBS-B) and blocked for 45 min in 20% serum–PBS-B, corresponding to the secondary
detection antibody species. Primary and secondary detection antibodies were applied for 1 h each at
room temperature in PBS-B. Immunoﬂuorescence was preserved with SlowFade Gold antifade reagent
with DAPI (4=,6-diamidino-2-phenylindole; Invitrogen) and mounted on glass slides for confocal or
epiﬂuorescence microscopy. M2 anti-FLAG ﬂuorescein isothiocyanate (FITC) conjugate antibody (Sigma)
was used for detection of FLAG-tagged murine ISG20 and IG20D94G. Percentages of infected cells were
calculated by counting the number of GFP cells/total number of DAPI nuclei in the ﬁeld.
Translation reporters and double electroporation. The nonreplicating host, EMCV, and CHIKV
translation reporters were produced as described previously (2, 51). The cricket paralysis virus (CrPV)
translation reporter, a gift from Martin Bushell, Medical Research Council, United Kingdom, was described
previously (52). tet-off MEFs were induced on 150-mm-diameter dishes as described above for ectopic
expression of the gene of interest. Induced cells were trypsinized and washed once in Opti-MEM.
Approximately 3 107 cells were resuspended in 1 ml of Opti-MEM per reaction and electroporated with
7.5 g of the indicated reporter RNA and 750 ng of Renilla luciferase mRNA using a Bio-Rad GenePulser
(220 V, 1,000 F, 2 pulses). Electroporated cells were diluted in doxycycline-free media and divided into
96-well plates. Cells were collected at the indicated time points by centrifugation, washed once in PBS,
and lysed in luciferase passive lysis buffer. A 25-l volume of collected lysates was assayed by
dual-luciferase assay (Promega) and normalized to protein concentrations as determined by BCA protein
assay (Thermo Scientiﬁc). For the double-electroporation experiment, MEFs were electroporated with
7 g of the CHIKV translation reporter as described above. Cells were washed in PBS and incubated in
doxycycline-free media for 0 h or 3 h. At each time point, cells were washed with PBS and added to Tri
reagent (Molecular Research Center). RNA was extracted according to the manufacturer’s guidelines and
resuspended in Opti-MEM. The freshly isolated RNA was then reelectroporated into MEFs expressing
either eGFP or ISG20 and incubated for 3 h in doxycycline-free media. At 3 h, lysates were collected for
luciferase analysis using a ﬁreﬂy luciferase assay system (Promega). Luciferase activity arising from the
second transfection is given as a ratio of ﬁreﬂy luciferase signal from 3 h versus 0 h samples correspond-
ing to the ﬁrst transfection.
Cycloheximide treatment of tet-off MEFs. For cycloheximide treatment, GFP, ISG20, or ExoII tet-off
MEFs were infected with CHIKV (MOI 5) expressing nLuc in frame with the nsP3 nonstructural protein
for 1 h. After washing, medium containing either 0 or 10 M of cycloheximide (Sigma) was added for the
duration of the experiment to block translation. At indicated time points, cells were washed with PBS and
lysed with 1 passive lysis buffer (Promega). A 25-l volume of collected lysates was assayed by
Nano-Glo luciferase assay (Promega) and normalized to protein concentrations as determined by BCA
protein assay (Thermo Scientiﬁc). Data are represented as relative luminescence units per microgram of
protein (RLU/g). For RNA degradation experiments, MEFs were infected with CHIKV-LR (MOI  0.1) and
treated with 10 M cycloheximide. At the indicated time points, the cells were washed and placed in Tri
reagent (Molecular Research Center) according to manufacturers’ guidelines. cDNA was reverse tran-
scribed using random hexamers from 100 ng of Tri reagent-extracted RNA and detected by quantitative
PCR (qPCR) with SYBR green on a MiniOpticon thermal cycler and detection unit (Bio-Rad) using the
following primers: CHIKV-3=NTR-F (5=-ATA ATT GGC AAA CGG AAG AGA T-3=) and CHIKV-3=NTR-R (5=-ACA
AAA TAA CAT CTC CTA CGT CC-3=).
RNA sequencing. Total cellular RNA from two separately derived clones of tet-off MEFs expressing
eGFP, Isg20, or ISG20D94G was isolated and depleted of rRNA with Ambion RiboMinus Eukaryote kit v2
(Life Technologies). Directional sequencing libraries were generated using an NEBNext Ultra Directional
RNA Library Prep kit for Illumina with NEBNext Primer Set 1 (New England BioLabs). Multiplexed libraries
were sequenced with 100-bp paired-end reads on an Illumina HiSeq 2000 platform (Axeq Technologies).
Reads were aligned to the iGenome-indexed Mus musculus genome UCSC mm9 (Illumina) using Tophat,
and differential gene expression was determined using Cufﬂinks (53). Pathway analysis of differentially
regulated genes was performed using Ingenuity pathway analysis (Qiagen).
qRT-PCR. Forward and reverse primers for qRT-PCR were designed as follows: for Isg20-F, 5=-AAC ATC
CAG AAC AAC TGG CGG-3=; for Isg20-R, 5=-GTC TGA CGT CCC AGG GCA-3=; for Irgm2-F, 5=-GCG ATA GAG
ATT CGG AAA GC-3=; for Irgm2-R, 5=-CAG CAC CCA GTC ATC TTG TT-3=; for Usp18-F, 5=-AGG AGT CCC TGA
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TTT GCG TG-3=; for Usp18-R, 5=-GGG TTT TCA GAG GCT TTG CG-3=; for Iﬁt3-F, 5=-AGA TTT CTG AAC TGC
TCA GCC C-3=; for Iﬁt3-R, 5=-CAG AGA TTC CCG GTT GAC CTC-3=; for Irf7-F, 5=-ATT TCG GTC GTA GGG ATC
TG-3=; for Irf7-R, 5=-GTT GGT CTT CCA GCC TCT TC-3=; for Iﬁ44-F, 5=-ACT CGT TTG ACA TGG CAG CA-3=; for
Iﬁ44-R, 5=-TCT GCA CAC TCG CCT TGT AA-3=; for Iﬁt1-F, 5=-GTG GCT CAC ATA GAG CAG GA-3=; for Iﬁt1-R,
5=-AGT TTC CTC CAA GCA AAG GA-3=; for Oas1a-F, 5=-TCC ACA GTA CGC CCT AGA GT-3=; for Oas1a-R,
5=-GAC CAG TTC CAA GAC GGT CC-3=; for Igtp-F, 5=-TCT GAG CAG GTT CTG AAG GA-3=; for Igtp-R, 5=-TCC
TCG GCT TCT TTC TTC TC-3=; for Isg15-F, 5=-TCC ATG ACG GTG TCA GAA CT-3=; for Isg15-R, 5=-GAC CCA
GAC TGG AAA GGG TA-3=; for Iﬁt2-F, 5=-AGA ATT CAC CTC TGG ATG GG-3=; for Iﬁt2-R, 5=-GTC AAG CTT
CAG TGC CAA GA-3=; for Irf3-F, 5=-GCG GTT AGC TGC TGA CAA TA-3=; for Irf3-R, 5=-AGG CCA TCA AAT AAC
TTC GG-3=, for 18S-F, 5= CGC CGC TAG AGG TGA ATT TCT-3=; and for 18S-R, 5= CGA ACC TCC GAC TTT CGT
TCT-3=. qRT-PCR primers for CHIKV positive-strand RNA detection were as previously described (54).
cDNA was reverse transcribed with random hexamers from 100 ng of Tri reagent-extracted RNA and
detected by qPCR with SYBR green on a MiniOpticon thermal cycler and detection unit (Bio-Rad). Fold
induction was determined for genes of interest using the cycle threshold (ΔΔCT) method.
Promoter activation reporters. Construction of promoter luciferase plasmids pRL-SV40, pLUX (a
gift from Barbara Sherry, North Carolina State University) (55), and PRDI/III or PRDII (gifts from Tom
Maniatis, Harvard University) (56) was described previously. GFP, ISG20, and ExoII MEFs were induced in
24-well cluster plates for expression of the target protein for 3 days as described above. Promoter
luciferase plasmid (0.5 g/well) and simian virus 40 (SV40) promoter-driven Renilla luciferase control
plasmid (0.25 g/well) were transfected into MEFs using TransIT-LT1 reagent (Mirus) and incubated for
24 h. Cells were treated 16 h prior to harvest with 0.3 g poly(I·C)–TransIT-LT1 reagent or transfection
reagent alone. Lysates were collected in passive lysis buffer and measured by dual-luciferase assay
(Promega). Fireﬂy luciferase RLUs were normalized to Renilla RLUs in each cell and are represented as
percentages of untreated GFP control cells.
siRNA knockdown of IRF3 in MEFs. GFP, ISG20, and ExoII MEFs were induced as described above.
After 24 h, 25 nm of SMARTpool siRNA Irf3 (Dharmacon) or 25 nm of SMARTpool nontargeting siRNA
(Dharmacon) was transfected into MEFs using DharmaFECT 1 transfection reagent according to manu-
facturer’s guidelines. After 48 h, cells were washed and used for RT-PCR analysis of indicated genes. Data
were normalized to 18S values, and fold change compared to sham-treated control GFP cell results is
graphed.
Mice and infections. Male or pregnant female C57BL/6J (B6) mice were purchased from the Jackson
Laboratory. Isg20/ mice were generated at Washington University after receiving heterozygous
Isg20/ sperm from C57BL/6 mice containing a promoter knockout [Isg20tm1a(KOMP)Wtsi] from the
Knockout Mouse Project Repository (KOMP; University of California, Davis). The sperm was used for in
vitro fertilization of eggs from B6 recipient female mice. Heterozygous Isg20/ mice were backcrossed
to establish the Isg20/ colony. Isg20/ mice produced normal litter sizes of expected Mendelian
ratios, with all progeny appearing healthy. Mice were used at 1 day or 3 weeks of age for CHIKV infection
and at 6 weeks of age for VEEV infection. CHIKV (103 PFU) was inoculated subcutaneously in the left rear
footpad in 10 l of Opti-MEM. VEEV was inoculated subcutaneously in each rear footpad with 103 PFU
for a total of 2  103 PFU per animal. Disease was monitored by changes in weight and clinical scoring
speciﬁc to the disease manifestations of each virus every 12 to 24 h. For virus titration, RNA isolation, and
IFN bioassay, serum was collected from submandibular vein, and mice were euthanized and perfused
with 10 ml of PBS before tissue collection. Tissues were collected in 100 l of PBS–1% bovine serum per
gram of tissue and mechanically dissociated, and virus titers were determined by BHK-21 plaque assay
performed on the resulting supernatants. Serum was assayed for functional type I IFN using a bioassay
as previously described (57). All animal experiments were conducted under the guidance of protocols
approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh.
Generation and infection of primary cells. Osteoblasts were prepared by dissecting calvaria from
4-day-old pups and manually removing surrounding tissue. Calvaria were washed in PBS and digested
in two 20-min digestions and one 90-min digestion in -MEM with 96 g/ml collagenase P and 0.01%
trypsin–EDTA on a shaking 37°C incubator. Digested calvaria were washed in PBS and suspended in
-MEM supplemented with 10% FBS, 10,000 units/ml penicillin, and 10 mg/ml streptomycin for 5 days
undisturbed on 100-mm-diameter cell culture dishes. Osteoblasts were trypsinized and expanded for two
passages on T-75 ﬂasks prior to infections.
Primary MEFs were prepared from pregnant mice at 14 days of gestation. The head and liver was
removed from individual embryos, and specimens were rinsed in PBS. Embryos were minced in ice-cold
0.25% trypsin–EDTA solution and then heated to 37°C for 30 min in a water bath. MEFs were homoge-
nized by serial passage through 18- and 23-gauge needles. Cells were washed and resuspended in DMEM
supplemented with 10% heat-inactivated FBS, 10,000 units/ml penicillin, and 10 mg/ml streptomycin.
MEFs were expanded to passage 2 for individual experiments. For infection, cells were treated with 0, 10,
or 100 IU/ml of IFN-4/ (1:1 ratio) for 4 h, washed, and then infected with either CHIKV or VEEV-G3A at
an MOI of 1 for 1 h. The cells were washed thrice with PBS, and medium speciﬁc for each cell type was
added. Virus was collected at 24 h.p.i., and titers were determined by plaque assay on BHK-21 cells. For
RT-PCR, primary B6 or Isg20/ MEFs were treated with 0, 10, or 100 IU/ml of IFN-4/ (1:1 ratio) for 6 h,
washed with PBS, and placed in Tri reagent for RNA isolation and qRT-PCR for indicated genes.
Statistical analysis. The statistical model for differential gene expression by RNA-seq was described
in detail previously (58). All other statistical analyses were performed in GraphPad PRISM. Analysis of
variance (ANOVA) was performed with Dunnett’s multiple-comparison test. Two-way ANOVA was
performed with the Holm-Sidak multiple-comparison test. Two-tailed Mann-Whitney and Student’s t tests
were performed for   0.05.
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